Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Linnea Lebaron

Advanced Heart Failure and Transplant Cardiology Little Rock, AR Doctor of Osteopathy

NPI 1104287747 CMS profile 2056327

9500 Kanis Rd Ste 410, Little Rock, AR 72205

Open in the dashboard

General payments

$13,217

296 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Linnea Lebaron of Little Rock, AR is reported in the CMS Open Payments database as having received $13,217 across 296 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,577 70
2024 General $902 43
2023 General $2,231 61
2022 General $2,555 39
2021 General $2,205 28
2020 General $623 19
2019 General $3,124 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Linnea Lebaron
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Linnea Lebaron were reported at $1,577. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Linnea Lebaron Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $3,124 $863 $224–$4,562 $163
2020 $623 $452 $122–$3,992 $114
2021 $2,205 $550 $159–$3,571 $132
2022 $2,555 $729 $221–$4,357 $149
2023 $2,231 $1,002 $309–$5,827 $160
2024 $902 $931 $273–$5,204 $164
2025 $1,577 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $6,327 72 payments
  2. Biotronik Inc. $2,432 14 payments
  3. AstraZeneca Pharmaceuticals LP $550 24 payments
  4. Actelion Pharmaceuticals US, Inc. $509 24 payments
  5. United Therapeutics Corporation $373 10 payments
  6. Merck Sharp & Dohme Corporation $364 18 payments
  7. Pfizer Inc. $352 22 payments
  8. Novartis Pharmaceuticals Corporation $300 18 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $284 17 payments
  10. Abiomed $269 3 payments
  11. Other $1,455 74 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,547 270 payments
  2. Travel and Lodging $5,302 21 payments
  3. Education $368 5 payments
Products named General payments · program years 2019–2025
  1. THORATEC HEARTMATE 3 LVAS IMPLANT KIT Heart failure $3,397 40 payments
  2. HeartMate Touch $1,897 13 payments
  3. OPSUMIT $509 24 payments
  4. CardioMEMS HF System $421 4 payments
  5. UPTRAVI $332 12 payments
  6. THORATEC HEARTMATE 3 LVAS IMPLANT KIT Structural Heart $329 10 payments
  7. VERQUVO $300 15 payments
  8. Impella $269 3 payments
  9. VYNDAQEL $253 16 payments
  10. CAMZYOS $243 13 payments
  11. Other $3,212 154 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

1,495

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$628,355

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

21.5%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Adempas Riociguat Brand 15 $207,370
Opsumit Macitentan Brand 16 $197,634
Entresto Sacubitril/Valsartan Brand 83 $83,339
Jardiance Empagliflozin Brand 70 $53,947
Eliquis Apixaban Brand 27 $24,552
Farxiga Dapagliflozin Propanediol Brand 20 $13,018
Envarsus Xr Tacrolimus Brand 12 $11,972
Corlanor Ivabradine Hcl Brand 19 $9,454
Xarelto Rivaroxaban Brand 14 $9,389
Sildenafil Citrate Generic 36 $2,585

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$60,729

Medicare's payments for the services billed

Medicare patients

145

Average age 66

Services billed

882

57 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 73%
Chronic kidney disease 68%
Atrial fibrillation 66%
Diabetes 46%
Arthritis 40%
COPD 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TYVASO
  • United Therapeutics Corporation $120
$120 — —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $108
$108 16 —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $74
$74 — —
VYNDAQEL
  • PFIZER INC. $70
$70 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $66
$66 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

296 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record